An observational study in Hepatocellular Carcinoma (HCC), sponsored by Anhui Provincial Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Anhui Provincial Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Carcinoma, Hepatocellular by Anhui Provincial Hospital — 6 open to participants now, 7 under way, none of them phase 3. Carcinoma, Hepatocellular · Anhui Provincial Hospital.
Among the 10 studies in Carcinoma, Hepatocellular by Anhui Provincial Hospital, this one is the only one that started in 2019, is one of 3 observational ones, and was the 9th registered.
3,650 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.
Browse Carcinoma, Hepatocellular studies →6 of the 10 studies in Carcinoma, Hepatocellular by Anhui Provincial Hospital are open now, in 1 country. Recruiting first, the newest first:
Anhui Provincial Hospital · Sites in China
Ages 18–75
Anhui Provincial Hospital · Sites in China
Ages 18–70
Anhui Provincial Hospital · Sites in China
Ages 18–80
Anhui Provincial Hospital · Sites in China
Ages 18–70
Anhui Provincial Hospital
Ages 18–75
By country, each count listing its studies:
Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 467 is above the median of 200 across 851 observational studies indexed under Carcinoma, Hepatocellular.
Median enrollment 47 across the 7 interventional studies, 555 across the 3 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Anhui Provincial Hospital is the lead sponsor of 135 studies on the registry; 101 are open to participants now.
4 of the studies in Carcinoma, Hepatocellular by Anhui Provincial Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07782632Anhui Provincial HospitalLiver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma | 2026-12-30 |
| NCT07150624Anhui Provincial HospitalThe Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine | 2026-12-31 |
| NCT06498622Anhui Provincial HospitalAdjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab | 2027-05-20 |
| NCT07793695Anhui Provincial HospitalOral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma | 2027-08-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies in Carcinoma, Hepatocellular by Anhui Provincial Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multicenter retrospective cohort study aims to evaluate the prognostic value of functional liver volume and total liver volume in patients with unresectable hepatocellular carcinoma (HCC) undergoing immunotherapy. The study explores whether baseline liver volume metrics can effectively predict survival outcomes and treatment responses in this patient population to assist in clinical decision-making.
This study retrospectively analyzes the clinical, laboratory, and imaging data of patients with unresectable hepatocellular carcinoma (HCC) who received immunotherapy across multiple clinical centers. Pre-treatment imaging data will be utilized to segment and quantify functional liver volume and total liver volume. Statistical and survival analyses will be performed to evaluate the correlation between these volumetric metrics and patient prognosis, including overall survival and progression-free survival, aiming to establish a robust stratification approach for individualized treatment strategies.
Patients diagnosed with unresectable hepatocellular carcinoma (HCC) who received immunotherapy across multiple medical centers, including the First Affiliated Hospital of University of Science and Technology of China, Zhengzhou University First Affiliated Hospital, and Fuyang Second People's Hospital, who met all specified inclusion and exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A multicenter retrospective cohort consisting of patients with unresectable hepatocellular carcinoma (HCC) who received immunotherapy. Baseline pre-treatment clinical and imaging data are reviewed to segment and evaluate functional liver volume and total liver volume metrics. These volumetric parameters are analyzed to determine their prognostic value regarding survival outcomes and treatment responses in this patient population.
Other: Baseline Liver Volume Volumetric Analysis
An observational evaluation based on the quantification of baseline pre-treatment functional liver volume (FLV) and total liver volume (TLV) derived from imaging datasets. These liver volume metrics are analyzed in correlation with clinical data to assess their prognostic potential for treatment response and overall survival in patients with unresectable hepatocellular carcinoma (HCC) receiving immunotherapy. No experimental treatment allocation or clinical intervention is performed.
Overall Survival (OS)
Overall survival is defined as the time from the initiation of immunotherapy to the date of death from any cause, or the date of the last follow-up for surviving patients.
Time frame: Up to 36 months
Overall Survival (OS)
Overall survival is defined as the time from the initiation of immunotherapy to the date of death from any cause, or the last follow-up date for surviving patients.
Time frame: Up to 36 months
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2019 (actual). Primary completion is estimated for Dec 2026, 95 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.